Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968732 · ClinicalTrials.gov registry record · NA
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
A NA study of Urothelial Carcinoma, sponsored by Fox Chase Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT02968732: Active NA study of Urothelial Carcinoma, sponsored by Fox Chase Cancer Center.
NCT02968732 is a NA study of Urothelial Carcinoma that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 65 participants, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02968732, a NA study of Urothelial Carcinoma, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, investigational study to assess the accuracy of standardized cystoscopic evaluation with tissue sampling performed immediately prior to definitive radical cystectomy to predict pathologic tumor stage and identify patients who may benefit from bladder preservation therapy.
Primary Outcome
Endoscopic assessments will be performed using a novel scoring system that allows objective quantification of endoscopic findings at the time of cystoscopy. The findings will be compared to final pathological specimen to determine reliability of predicting pTO disease from endoscopic assessment
Conditions Studied
Interventions
- PROCEDURE Radical Cystectomy
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-11-11 |
| Est. Completion | 2027-04-01 |
| Phase | NA |
What the registry record for NCT02968732 still lists
NCT02968732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Radical Cystectomy is the first listed.
NCT02968732 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02968732 about?
NCT02968732 is a clinical study titled "Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder". A prospective, investigational study to assess the accuracy of standardized cystoscopic evaluation with tissue sampling performed immediately prior to definitive radical cystectomy to predict pathologic tumor stage and identify patients who may benefit from bladder preservation therapy.
What is the current status of trial NCT02968732?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2016-11-11. Estimated completion is 2027-04-01.
What conditions does trial NCT02968732 study?
This clinical trial studies the following conditions: Urothelial Carcinoma.
What interventions are being tested in trial NCT02968732?
The interventions under investigation include: Radical Cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT02968732?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02968732 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02968732's enrollment target sits among peer trials
65 46th of 85 higher than 40 of 85 other Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
-
Bladder Cancer Screening Trial
RECRUITING · NA
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
RECRUITING · NA
-
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
RECRUITING · NA
-
Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI